Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma
FREMONT, Calif., June 25, 2014 (GLOBE NEWSWIRE) -- Quark Pharmaceuticals, Inc. today announced that the first patient has been dosed in a double-masked, randomized sham controlled Phase IIa safety, tolerability and pharmacokinetics study of Quark's proprietary neuroprotective agent QPI-1007 when administered by single intravitreal (IVT) injection in patients suffering an acute attack of primary angle closure glaucoma (PACG). QPI-1007 is a siRNA designed to temporarily inhibit the expression of Caspase 2, a protein that has been shown to play a role in retinal ganglion cell (RGC) cell death. QPI-1007 is currently under investigation for the treatment of non-arteritic ischemic optic neuropathy (NAION). In a Phase I/IIa multicenter clinical study recently completed in the USA and Israel a single intravitreal injection of QPI-1007 resulted in a neuroprotective effect in NAION patients.
Help employers find you! Check out all the jobs and post your resume.